Sonnet BioTherapeutics Holdings (STU:H3D) Total Current Assets: €1.14 Mil (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:H3D Sonnet BioTherapeutics Holdings Inc STU:H3D
28 GF Score
Price €44.00
View Full Analysis

What is Sonnet BioTherapeutics Holdings Total Current Assets?

Sonnet BioTherapeutics Holdings STU:H3D 28 Total Current Assets is €1.14 Mil as of Jun. 2025. GuruFocus rates STU:H3D with a GF Score™ of 28/100.

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Sonnet BioTherapeutics Holdings's total current assets for the quarter that ended in Jun. 2025 was €1.14 Mil.

Sonnet BioTherapeutics Holdings  (STU:H3D) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Sonnet BioTherapeutics Holdings's Liquidation Value for the quarter that ended in Jun. 2025 is

Liquidation value
= Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=0.278-4.423+0.75 * 0+0.5 * 0
=-4.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sonnet BioTherapeutics Holdings Total Current Assets Related Terms

Sonnet BioTherapeutics Holdings Total Current Assets Historical Data

* Premium members only.

The historical data trend for Sonnet BioTherapeutics Holdings's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sonnet BioTherapeutics Holdings Total Current Assets Chart

Sonnet BioTherapeutics Holdings Annual Data
Trend Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
Total Current Assets
Get a 7-Day Free Trial 6.49 24.49 5.47 4.44 1.91

Sonnet BioTherapeutics Holdings Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25
Total Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.76 1.91 6.42 3.01 1.14
STU:H3D
28GF Score
Sonnet BioTherapeutics Holdings Inc STU:H3D
Total Current Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sonnet BioTherapeutics Holdings Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Sonnet BioTherapeutics Holdings's Total Current Assets for the fiscal year that ended in Sep. 2024 is calculated as

Total Current Assets=Cash, Cash Equivalents, Marketable Securities+Total Receivables+Total Inventories+Other Current Assets
=0.134+0.687+0+1.087
=1.91

Sonnet BioTherapeutics Holdings's Total Current Assets for the quarter that ended in Jun. 2025 is calculated as

Total Current Assets=Cash, Cash Equivalents, Marketable Securities+Total Receivables+Total Inventories+Other Current Assets
=0.278+0.518+0+0.348
=1.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Frequently Asked Questions Learn more about Total Current Assets →
What does a Total Current Assets of €1.14 Mil mean?
Sonnet BioTherapeutics Holdings (STU:H3D) has a Total Current Assets of €1.14 Mil as of Jun. 2025. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Sonnet BioTherapeutics Holdings and its competitors.
Is Sonnet BioTherapeutics Holdings' Total Current Assets too high?
Sonnet BioTherapeutics Holdings' current Total Current Assets is €1.14 Mil. Overall, Sonnet BioTherapeutics Holdings has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Sonnet BioTherapeutics Holdings' Total Current Assets compare to CING and BOLD?
Sonnet BioTherapeutics Holdings' Total Current Assets of €1.14 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Assets for a Biotechnology company?
A good Total Current Assets depends on the Biotechnology industry context. However, Total Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Assets mean?
A high Total Current Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Sonnet BioTherapeutics Holdings and its competitors. Sonnet BioTherapeutics Holdings's current Total Current Assets is €1.14 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sonnet BioTherapeutics Holdings stock overvalued right now?
Sonnet BioTherapeutics Holdings (STU:H3D) has a current Total Current Assets of €1.14 Mil. The current Total Current Assets is €1.14 Mil. Sonnet BioTherapeutics Holdings' overall GF Score™ is 28/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Assets calculated?
Total Current Assets is calculated from a company's financial statements. For Sonnet BioTherapeutics Holdings (STU:H3D), the current Total Current Assets is €1.14 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sonnet BioTherapeutics Holdings Business Description

Address 100 Overlook Center, Suite 102, Princeton, NJ, USA, 08540
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.
28GF Score

Get the complete analysis for STU:H3D

Total Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€44.00
Price